MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202641084524 A) filed by Afroz Patan on July 09, 2026, for Novel 3-[3-(3-Amino-5-Bromo-4-Nitrophenyl)prop-2-Enoyl]-5-[(pyridin-4-Yl)methylidene]-1,3- Thiazolidine-2,4-Dione: Process For Its Preparation, Pharmaceutical Composition And Therapeutic Applications.
Inventors include Afroz Patan; M. Suchitra; Nalisetty Hari Chandana; Sireesha. V; V. Shobha; P. Saisireesha; Byju K; and Shaik. Munwar.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: Computational design and discovery study was carried out for the thiazolidinedione derivative in comparison with standard pioglitazone and propranolol against the Crystal structure of protein beta1-adrenoceptor (PDB ID: 4BV1) and PPARgamma (PDB ID: 6QJ5) proteins. Overall, our study revealed that the synthesized novel derivative of thiazolidinedione exhibited significant strong invitro as well as invivo antidiabetic and antihyperlipidemic effects. In silico studies were employed to explore interactions between the derivatives and target molecules. Molecular docking approaches used to discover the interaction between a tiny ligand and a target molecule. The overall findings from the docking study, ADME/T report, in vitro and in vivo activity results strongly suggest that the synthesized molecule hold promise as potential drug candidates with interesting pharmacological profiles. a pure crystalline product after systematic purification steps, confirmed via melting point determination and thin-layer chromatography. In vitro assays demonstrated potent alpha-amylase inhibition and reduced intracellular triglyceride accumulation in adipocyte models, while in vivo studies in streptozotocin-induced diabetic rats showed significant blood glucose lowering over 24 hours. Hypolipidemic effects were equally notable in Triton WR-1339 challenged animals, with marked decreases in serum cholesterol, LDL, and triglycerides. Acute toxicity evaluations confirmed a favorable safety profile at high doses. Overall, the derivative presents a compelling pharmacological profile, promising improved efficacy and patient compliance in managing these interconnected metabolic disorders.
Disclaimer: Curated by HT Syndication.
